Abstract
The results suggested that the real-time RT-RAA assay we developed was a specific, sensitive and reliable diagnostic tool for the rapid detection of IAVs.
Introduction
Influenza A viruses (IAVs) represent a persistent global health threat, characterized by rapid transmission and the potential for zoonotic spillover. Effective management of outbreaks necessitates fast and accurate diagnostic tools. Currently, reverse transcription quantitative PCR (RT-qPCR) is considered the "gold standard" due to its high sensitivity. However, RT-qPCR requires sophisticated thermal cyclers, specialized personnel, and several hours to complete, making it less ideal for point-of-care testing (POCT) or use in resource-limited field settings.
Methodology: Recombinase-Aided Amplification
To overcome the limitations of traditional PCR, this study developed a real-time reverse transcription recombinase-aided amplification (RT-RAA) assay. RAA is an isothermal nucleic acid detection technology that operates at a constant temperature (typically 37–42°C). Unlike PCR, which uses heat to denature DNA, RAA utilizes a recombinase enzyme to facilitate primer binding. The system also employs a single-stranded DNA-binding protein to maintain the unzipped state of the DNA and a strand-displacing DNA polymerase for amplification.
Assay Design and Target Selection
The researchers targeted the Matrix (M) gene, which is highly conserved across various IAV subtypes. This conservation ensures that the assay can function as a universal detector for Influenza A, regardless of the specific hemagglutinin (H) or neuraminidase (N) subtype.
The team performed extensive primer screening to identify the combination with the highest amplification efficiency. Real-time monitoring was achieved through the addition of a specific fluorescent "exo probe," allowing for immediate detection of the viral load.
Validation and Results
The assay's performance was evaluated using a panel of 12 reference IAV strains and several non-influenza respiratory viruses to ensure specificity. Furthermore, 120 clinical specimens (including lung tissue and various swabs) were tested to compare the RT-RAA assay against the standard RT-qPCR.
Key Performance Metrics
- Sensitivity: The RT-RAA assay achieved a 95% detection limit of 142 copies per reaction, which is statistically comparable to the 161 copies per reaction observed with RT-qPCR.
- Speed: Results are obtained within 20 minutes, a significant improvement over the 90–120 minutes required for RT-qPCR.
- Specificity: The assay demonstrated 100% specificity, showing no cross-reactivity with other common respiratory pathogens like SARS-CoV-2 or Influenza B.
- Clinical Concordance: There was 100% agreement between RT-RAA and RT-qPCR results across all 120 clinical samples.
Discussion and Future Directions
The isothermal nature of the RT-RAA assay (operating at a steady 42°C) drastically reduces hardware requirements. The test could potentially be performed using simple equipment like a heat block or water bath, making it highly suitable for portable diagnostic kits.
Despite these advantages, some limitations remain. The current workflow still relies on standard RNA extraction methods, which can be time-consuming. Future developments should focus on "extraction-free" protocols to further streamline the process. Additionally, while the assay is an excellent screening tool for Influenza A, it does not currently distinguish between specific subtypes (e.g., H1N1 vs. H3N2), which is necessary for detailed epidemiological tracking.
Conclusion
The real-time RT-RAA assay developed in this study provides a rapid, sensitive, and reliable alternative to traditional PCR for the detection of Influenza A. Its speed and simplicity make it a promising candidate for enhancing diagnostic capabilities in both clinical and field environments.
Summary updated